Dr. Reddy's Launches COVID-19 Pneumonia Treatment in India

Hyderabad based Dr. Reddy's Laboratories announced on September 9, 2020, the launch of Redyx, a potential treatment for COVID-19 pneumonia in India. The launch is part of the licensing agreement with Gilead Sciences, Inc. that grants Dr. Reddy’s rights to register, manufacture and sell Remdesivir, in 127 countries, including India.

In the USA, Remdesivir is known as Veklury.

Recently, the U.S. FDA broadened the scope of Veklury's authorization to include treatment of all hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19, irrespective of their severity of the disease, as of August 28, 2020.